NCT04544189: An ongoing trial by Novartis Pharmaceuticals
This trial is ongoing. It must report results 10 months, 4 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04544189 |
|---|---|
| Title | A Phase II Randomized Double-blind, Placebo-controlled Study of Alpelisib in Combination With Fulvestrant for Chinese Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, PIK3CA Mutant Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor (AI) Treatment, Including a Subset With Pharmacokinetic Analysis |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 20, 2021 |
| Completion date | March 2, 2026 |
| Required reporting date | March 2, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |